Explore innovative solutions reshaping the high-cost specialty drug landscape with Sally-Ann Polson, MBA, the President and CEO of MedWatch, LLC and Byron Harris, PharmD, the Vice President of Pharmacy Solutions for MRIoA.
During this webinar, we discussed:
- How to drive a 15:1* ROI by leveraging a proven high-cost specialty drug review program.
- How to achieve success in peer-to-peer consultations for high-cost specialty drugs by utilizing therapeutic interchange and optimizing site of service.
- The art of reviewing clinical appropriateness, ensuring that all approvals for high-cost specialty drugs align with the highest standards of clinical necessity.